CN115251339A - 一种通过调节肠道菌群增加骨密度的功能食品组合物及其制备方法 - Google Patents
一种通过调节肠道菌群增加骨密度的功能食品组合物及其制备方法 Download PDFInfo
- Publication number
- CN115251339A CN115251339A CN202110399300.1A CN202110399300A CN115251339A CN 115251339 A CN115251339 A CN 115251339A CN 202110399300 A CN202110399300 A CN 202110399300A CN 115251339 A CN115251339 A CN 115251339A
- Authority
- CN
- China
- Prior art keywords
- parts
- food composition
- bone
- intestinal flora
- inulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 14
- 210000000988 bone and bone Anatomy 0.000 title abstract description 49
- 229910052500 inorganic mineral Inorganic materials 0.000 title abstract description 21
- 239000011707 mineral Substances 0.000 title abstract description 21
- 235000013376 functional food Nutrition 0.000 title abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 43
- 235000013305 food Nutrition 0.000 claims abstract description 35
- 230000037182 bone density Effects 0.000 claims abstract description 33
- 240000008067 Cucumis sativus Species 0.000 claims abstract description 26
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 26
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 24
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 24
- 241000237502 Ostreidae Species 0.000 claims abstract description 23
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 23
- 244000235659 Rubus idaeus Species 0.000 claims abstract description 23
- 235000007215 black sesame Nutrition 0.000 claims abstract description 23
- 235000020636 oyster Nutrition 0.000 claims abstract description 23
- 229920001202 Inulin Polymers 0.000 claims abstract description 21
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 21
- 229940029339 inulin Drugs 0.000 claims abstract description 21
- 235000011034 Rubus glaucus Nutrition 0.000 claims abstract description 19
- 235000009122 Rubus idaeus Nutrition 0.000 claims abstract description 19
- 244000013123 dwarf bean Species 0.000 claims abstract description 15
- 235000021278 navy bean Nutrition 0.000 claims abstract description 15
- 235000001188 Peltandra virginica Nutrition 0.000 claims abstract description 8
- 230000036541 health Effects 0.000 claims abstract description 5
- 244000197580 Poria cocos Species 0.000 claims description 22
- 239000002994 raw material Substances 0.000 claims description 7
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000006187 pill Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 238000010521 absorption reaction Methods 0.000 abstract description 9
- 210000003734 kidney Anatomy 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 210000003205 muscle Anatomy 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 210000000952 spleen Anatomy 0.000 abstract description 4
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 230000001143 conditioned effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 26
- 208000001132 Osteoporosis Diseases 0.000 description 25
- 239000000463 material Substances 0.000 description 11
- 210000000689 upper leg Anatomy 0.000 description 11
- 235000013402 health food Nutrition 0.000 description 10
- 102000008108 Osteoprotegerin Human genes 0.000 description 9
- 108010035042 Osteoprotegerin Proteins 0.000 description 9
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 9
- 210000004291 uterus Anatomy 0.000 description 9
- 230000009102 absorption Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000004097 bone metabolism Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical group C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000010392 Bone Fractures Diseases 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 206010017076 Fracture Diseases 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 235000021013 raspberries Nutrition 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000001694 thigh bone Anatomy 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- 206010065687 Bone loss Diseases 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical group NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 description 2
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 2
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000035484 Cellulite Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 2
- 206010049752 Peau d'orange Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 210000003489 abdominal muscle Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003262 anti-osteoporosis Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 238000003766 bioinformatics method Methods 0.000 description 2
- 229940069978 calcium supplement Drugs 0.000 description 2
- 230000036232 cellulite Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960000452 diethylstilbestrol Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 238000010603 microCT Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940005605 valeric acid Drugs 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001456553 Chanodichthys dabryi Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124605 anti-osteoporosis drug Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002876 effect on osteoporosis Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 244000209700 shan ge teng Species 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/30—Mashed or comminuted products, e.g. pulp, pastes, meal, powders; Products made therefrom, e.g. blocks, flakes, snacks; Liquid or semi-liquid products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/50—Molluscs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Agronomy & Crop Science (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明属于食品和保健品技术领域,具体涉及一种通过调节肠道菌群增加骨密度的功能食品组合物及其制备方法。一种通过调节肠道菌群增加骨密度的多功能食品组合物,由如下重量份数的组分组成:黄瓜籽粉20~25份、葛根8~20份、覆盆子8~15份、黑芝麻2~4份、牡蛎2~4份、茯苓2~4份、菊粉1~3份、白芸豆粉1~2份。本发明提供的食品组合物以中医药组方理论为指导,并通过现代生物化学的手段进行验证,具有非常显著的增加骨密度的作用。配方中的各药物成分协同起效,通过调节肠道菌群促进矿物质吸收实现对骨骼的调理。本发明提供的多功能食品组合物补肾健脾,活血通络,标本兼顾,即脾健肾精充足,络通而气血旺,致精血充沛,则筋骨强健。
Description
技术领域
本发明属于食品和保健品技术领域,具体涉及一种通过调节肠道菌群增加骨密度的功能食品组合物及其制备方法。
背景技术
骨质疏松症(osteoporosis),随着社会人口老龄化加剧,已经成为疾病中的常见病和多发病,是以骨量减少、骨微结构退化为特征、导致骨脆性增高及骨折危险性增加的一种全身代谢性骨病,影响到全世界数以百万人。目前,我国骨质疏松患者已达9000万,而我国骨质疏松患者在1987~2017这30年间增加了300%,在50岁以上人群中,大约三分之一的女性和五分之一的男性在其余生中至少会经历一次骨质疏松性骨折。衰老、妇女绝经、疾病、药物和营养缺乏等均可引起骨骼矿物质的丢失,骨密度降低,出现腰酸背痛、驼背、最终导致骨质疏松,重者可造成骨折、致残、终身卧床。这种骨脆性增加的临床表现是由破骨细胞调节的骨吸收和成骨细胞调节的骨形成失衡引起的。在绝经后妇女中,衰老或激素缺乏会导致骨平衡的代谢紊乱,导致更高的骨转换率,骨形成的速度远不及骨流失的速度。绝经后激素替代疗法(HRT)可以减少骨质疏松性骨折和骨流失,但长期服用会产生诸多的副作用,如增加乳腺癌、子宫内膜癌和心血管等疾病风险。因此,寻找高效低毒的抗骨质疏松症药物是非常迫切和必要的。
很多人认为:人到老年,腰背疼,腿脚疼,是“缺钙”造成的!一般来说,骨质疏松症一旦出现明显的疼痛症状时,骨骼中的骨量已经丢失30%~50%以上了。目前抗骨质疏松保健品的作用机制主要以补钙为主,通过促进钙吸收增加骨密度,但是由于靶点过于单一,长期服用不良反应会增多药效减弱,如胃肠道反应、肾功能损害、钙易位沉积引起关节疼痛等。人们在不断补钙的过程中还会出现骨质疏松和矿物质的异位沉积,就是因为矿物质没有得到有效的吸收和利用。肠道菌群是生活在我们肠道内的共生细菌,具有许多调节功能,包括调节宿主代谢和免疫状态。近年来的研究表明,肠道菌群也是骨量的调节剂,并提出肠道菌群对骨量的影响是通过对免疫系统的影响而介导的,而肠道免疫系统反过来调节破骨细胞的生成同时促进矿物质的吸收。所以,通过调节肠道菌群促进矿物质吸收改善骨代谢是一种新的有效途径。
在传统中医药中,食品是重要的组成部分,一些传统食品可作为药物来治疗疾病,而一些常用于防治疾病的中药也逐渐在人们的日常饮食中出现,这些食品或中药被统称为药食同源中药。我国中医药治疗骨质疏松症的历史悠久,拥有丰富的药食同源的植物资源,毒副作用小,多成分多靶点共同调节机体的平衡,同时改善多方面的代谢。因此,从药食同源的药材中研发一种通过调节肠道菌群增加骨密度的功能食品组合物是安全有效的途径。
发明内容
针对上述现有技术中的不足,本发明提供了一种通过调节肠道菌群增加骨密度的功能食品组合物及其制备方法,制备工艺简单,疗效好,安全无副作用。
为实现上述目的,本发明采用以下技术方案。
一种通过调节肠道菌群增加骨密度的多功能食品组合物,由如下重量份数的组分组成:黄瓜籽粉20~25份、葛根8~20份、覆盆子8~15份、黑芝麻2~4份、牡蛎2~4份、茯苓2~4份、菊粉1~3份、白芸豆粉1~2份。
优选地,所述的多功能食品组合物,由如下重量份数的组分组成:黄瓜籽20份、葛根20份、覆盆子10份、黑芝麻3份、牡蛎4份、茯苓3份、菊粉3份、白芸豆粉1份。
优选地,所述的多功能食品组合物,由如下重量份数的组分组成:黄瓜籽25份、葛根15份、覆盆子10份、黑芝麻2份、牡蛎2份、茯苓3份、菊粉2份、白芸豆粉2份。
优选地,所述的多功能食品组合物,由如下重量份数的组分组成:黄瓜籽粉24份、葛根8份、覆盆子8份、黑芝麻4份、牡蛎2份、茯苓2份、菊粉2份、白芸豆粉1份。
所述通过调节肠道菌群增加骨密度的功能食品组合物的制备方法,具体包括以下步骤。
步骤1、将所述各组分原料除杂、净化、晾干后备用。
步骤2、将葛根、覆盆子、黑芝麻、茯苓在80℃的烘箱中烘干5h,再粉碎,过120目筛,得到细粉混合物A。
步骤3、牡蛎直接粉碎,合并黄瓜籽粉、菊粉和白芸豆粉过100目筛,得到细粉混合物B。
步骤4、将混合物A与混合物B均匀混合后制得所需剂型。
所述通过调节肠道菌群增加骨密度的功能食品组合物在制备增加骨密度、改善肠道菌群的的药物、食品和保健品中的用途。
进一步地,所述的多功能食品组合物加入辅料制备成不同制剂,所加入的辅料为药学上可接受的辅料。
所述制剂为口服制剂包括片剂,胶囊剂,散剂,颗粒剂,冲剂,泡腾剂或袋泡剂等。优选药物的剂型为颗粒剂、片剂、胶囊剂和袋泡剂。
本发明还可应用到不同食品中。
与现有技术相比,本发明的有益效果如下。
本发明提供的增加骨密度的多功能食品组合物中黄瓜籽、葛根、覆盆子、黑芝麻、牡蛎、茯苓、菊粉和白芸豆粉8味药材组合在一起,通过调理肠道菌群促进矿物质吸收,调理性补钙,达到增加骨密度的效果的保健食品还未见报道。所述增加骨密度的多功能食品组合物原料均选自国家卫计委2020年发布文件《按照传统既是食品又是中药材物质目录管理办法》征求意见稿的110种药食同源的药材,天然无害,适合长期服用。在平衡了性味归经之后,不会产生寒凉刺激。本发明作为一种组合物的保健品,其中黄瓜籽为老黄瓜籽,葛根为野葛富含大量的异黄酮类成分,牡蛎为牡蛎壳,富含碳酸钙。
本发明提供的增加骨密度的多功能食品组合物以中医药组方理论为指导,采用抗骨质疏松药效学参数为验证指标,筛选验证组方的合理性,疗效较佳的抗绝经后骨质疏松配方,按照传统的补肾壮骨中医理论以及中药系统药理学大数据分析得到治疗骨质疏松的组方,根据君臣佐使及药物配伍规律进行组方及拆方研究,并通过现代生物化学的手段进行验证,具有非常显著的增加骨密度的作用。在现有技术中没有利用本配方治疗骨质疏松的相关报道。配方中的各药物成分协同起效,通过调节肠道菌群促进矿物质吸收实现对骨骼的调理。本发明补肾健脾,活血通络,标本兼顾,即脾健肾精充足,络通而气血旺,致精血充沛,则筋骨强健。
本发明提供的增加骨密度的多功能食品组合物本利用TCMSP、DAVID等在线数据库的生物信息学分析手段对组合物主药材的成分、靶点进行了筛选和富集分析以支持本发明组方的合理性和全面性。
附图说明
图1为本发明增加骨密度的多功能食品组合物对股骨远心端骨小梁的影响2D图。
图2为本发明增加骨密度的多功能食品组合物对肠组织HE染色切片的影响。
图3-1至图3-4为本发明增加骨密度的多功能食品组合物对肠道菌群物种差异分析科水平的影响。
图4-1至图4-2为本发明增加骨密度的多功能食品组合物对粪便和血清中乙酸、丙酸、异丁酸、丁酸、异戊酸、戊酸、总短链脂肪酸的含量的影响。
具体实施方式
以下通过实施例形式,对本发明的上述内容再作进一步的详细说明,但不应将此理解为本发明上述主题的范围仅限于以下的实例,凡基于本发明上述内容所实现的技术均属于本发明的范围。
实施例1。
称取黄瓜籽20份、葛根20份、覆盆子10份、黑芝麻3份、牡蛎4份、茯苓3份、菊粉3份、白芸豆粉1份,然后按照如下方法制备实施例1的保健食品:步骤1、将所述各组分原料除杂、净化、晾干后备用;步骤2、将葛根、覆盆子、黑芝麻、茯苓在80℃的烘箱中烘干5h,再粉碎,过120目筛,得到细粉混合物A;步骤3、牡蛎直接粉碎,合并黄瓜籽粉、菊粉和白芸豆粉过100目筛,得到细粉混合物B;S4将混合物A与混合物B均匀混合。
实施例2。
称取黄瓜籽25份、葛根15份、覆盆子10份、黑芝麻2份、牡蛎2份、茯苓3份、菊粉2份、白芸豆粉2份;然后按照与实施例1相同的制备方法制备实施例2的保健食品。
实施例3。
称取黄瓜籽粉24份、葛根8份、覆盆子8份、黑芝麻4份、牡蛎2份、茯苓2份、菊粉2份、白芸豆粉1份;然后按照与实施例1相同的制备方法制备实施例3的保健食品。
实施例4。
称取葛根8份、覆盆子8份、黑芝麻4份、牡蛎2份、茯苓2份、菊粉2份、白芸豆粉1份;然后按照与实施例1相同的制备方法制备实施例4的保健食品。
实施例5。
称取黄瓜籽粉24份、覆盆子8份、黑芝麻4份、牡蛎2份、茯苓2份、菊粉2份、白芸豆粉1份;然后按照与实施例1相同的制备方法制备实施例5的保健食品。
实施例6。
称取黄瓜籽粉24份、葛根8份、黑芝麻4份、牡蛎2份、茯苓2份、菊粉2份、白芸豆粉1份;然后按照与实施例1相同的制备方法制备实施例6的保健食品。
实施例7。
称取黄瓜籽粉24份、葛根8份、覆盆子8份、牡蛎2份、茯苓2份、菊粉2份、白芸豆粉1份;然后按照与实施例1相同的制备方法制备实施例7的保健食品。
实施例8。
称取黄瓜籽粉24份、葛根8份、覆盆子8份、黑芝麻4份、牡蛎2份、菊粉2份、白芸豆粉1份;然后按照与实施例1相同的制备方法制备实施例7的保健食品。
实施例9本发明加骨密度的功能食品组合物组方合理性验证。
首先利用文献挖掘从古代方剂和国产保健食品数据库检索抗骨质疏松应用频次较多的中药材,从中选取药食两用的单味药:黄瓜籽、葛根、覆盆子、黑芝麻、牡蛎、茯苓。
通过以下数据库TcmSP数据库(http://sm.nwsuaf.edu.cn/lsp/tcmsp.php);TCMID数据库(http://www.megabionet.org/tcmid/);TCM Database@Taiwan数据库(http://tcm.cmu.edu.tw/);搜集各原料药的成分(OB>20%,DL>0.18),建立成分-靶点的网络图,将筛选到的靶点输入到Uniprot数据库中规范靶点名称,对应其基因名称。将所有靶点的基因名称上传至DAVID数据库,进行GO-BP的生物过程和KEGG的通路富集分析,筛选出与骨质疏松发生发展相关的靶点基因。应用Cytoscape3.3.1软件将入选的成分、靶点进行成分-靶点的网络构建,验证组方合理性,优选组方。
本发明的5味主要原料中药材共筛选出116个潜在活性成分,245个靶点,其中所富集到的与骨质疏松相关的靶点共计51个,肠道相关靶点71个,占到筛选靶点的1/5以上。排名前15的通路都与钙的吸收、骨代谢和肠道免疫过程息息相关,从生物信息学分析的角度,充分说明本发明组方的合理性和具有通过肠道菌群改善骨质疏松功能性的潜在性。
实施例10本发明加骨密度的功能食品组合物的方剂的筛选实验。
通过网络药理学的预测和传统中医理论组方,确定了组方中主药为黄瓜籽、葛根、覆盆子、黑芝麻、茯苓,然后按不同的配比进行组方的优选,即实施例1-3,对组方中的几味主药进行拆方,验证组方的合理性,减少方中黄瓜籽即实施例4,减少方中葛根即实施例5,减少方中覆盆子即实施例6,减少方中黑芝麻即实施例7,减少方中茯苓即实施例8。然后进行去势大鼠的灌胃给药,三个月后测量大鼠的骨密度。
1、造模。
大鼠腹腔注射30mg/kg戊巴比妥钠溶液麻醉,腹位固定后于腹中线距离阴道口3—4cm处去毛,分别用碘酒和酒精消毒,待稍干后切开皮肤和腹肌约2—3cm,切口视野可见白色脂肪,拨开脂肪层找到子宫后,轻轻将一侧子宫角拉出,在其末端可见被脂肪团包裹的卵巢。分离脂肪团,便可见粉红色或黄色的卵巢,以止血钳夹住卵巢,然后将卵巢下输卵管用线结扎,剪出卵巢,顺势将子宫角送回腹腔中,同法剪除另一侧卵巢。腹肌和皮肤分层缝合后,再次消毒。最后经后肢肌肉注射2万U青霉素。
2、动物分组与给药。
大鼠经适应性饲养后分组,按照发明组合物实施例1-7配置混悬液(按大鼠体重每kg等计量的生药材给药),实验动物按体重随机分组为切除卵巢+实施例1、切除卵巢+实施例2、切除卵巢+实施例3、切除卵巢+实施例4、切除卵巢+实施例5、切除卵巢+实施例6、切除卵巢+实施例7、切除卵巢+实施例8、切除卵巢组+溶剂组、假手术组。每组动物10只。每周称取体重,并按新体重调整灌胃剂量,给药3个月,各组大鼠自由饮水、摄食。
3、数据分析。
所有实验数据以平均数±标准差表示,用SPSS16.0进行t检验分析。
4、测定指标。
骨骼标本:采血后脱颈处死大鼠,完整分离大鼠的左右两侧股骨,剔除所有附着的肌肉和结缔组织,每只以10%甲醛溶液固定,进行病理学检查;一只用生理盐水浸泡的纱布包裹,保存于-80℃保存,分别测定股骨的骨密度。
用双能X射线骨密度仪测定股骨中点的骨密度。将待测骨放置于测量台上与骨密度仪探测头移动方向垂直;移动待测骨,令其待测点标记线与探测头移动轨迹于测量台上的垂直投影重合。开始测量股骨中点骨密度。
5、实验结果。
不同组大鼠股骨分别测定骨密度,见表1,模型组股骨中点骨密度降低,提示去卵巢后大鼠股骨的骨密度明显降低;实施例1、2、3不同程度地提高了骨密度,其中实施例3改善的最为明显;实施例4、5、6、7、8与造模组相比无显著性差异,提示拆掉主药中的任何一味药重新组方改善骨密度的药效都不如本发明组方好,证实了组方的合理性。最佳组方配比为实施例3。
组别 | 骨密度 |
实施例1 | 0.24±0.01* |
实施例2 | 0.23±0.01* |
实施例3 | 0.25±0.02** |
实施例4 | 0.22±0.01 |
实施例5 | 0.22±0.02 |
实施例6 | 0.21±0.01 |
实施例7 | 0.22±0.02 |
实施例8 | 0.21±0.03 |
造模组 | 0.21±0.02# |
假手术组 | 0.27±0.01 |
注:与模型组比较“*”P<0.05,“**”P<0.01,与假手术组比较“#”P<0.05(下同)。
实施例11本发明加骨密度的功能食品组合物药效学评价。
一、本发明抗骨质疏松的作用。
1、测定指标。
收集实施例3(OVX+F)、去势造模组(OVX)、阳性药己烯雌酚组(OVX+DES)和假手术组(Sham)的血清,测定骨代谢生化指标:大鼠酒石酸酸性磷酸酶5b(TRACP-5b),骨源性碱性磷酸酶(BALP),I性胶原羧基末端肽(CTX),骨保护素(OPG)。
骨骼标本:采血后脱颈处死大鼠,完整分离大鼠的左右两侧股骨,剔除所有辐照的肌肉和结缔组织,一只以10%甲醛溶液固定,进行病理学检查;一只用生理盐水浸泡的纱布包裹,保存于-80℃保存,分别测定股骨的皮质骨骨密度、骨小梁3D结构。
将大鼠右侧股骨从软组织中取材,清洗,固定在4%多聚甲醛中。采用Quantum GX型号微计算机断层扫描(μ-CT)系统(PerkinElmer micro-CT,USA)对其进行研究。使用30μm体素尺寸、90kv扫描股骨远端。对于小梁骨,在股骨远端2mm3的干骺端海绵区进行μ-CT评估。这些区域位于股骨生长板上方0.8mm处。使用Quantum GX 3.1.4软件对图像进行三维重建和可视化。三维重建后,使用Accuct Microct Analysis 12.0软件进行骨分析。计算或直接测量骨密度(BMD)、骨体积分数(BV/TV)、骨小梁厚度(TB.Th)和骨小梁间距(TB.Sp)的指标。
子宫标本:充分暴露并剥离取出子宫,电子天平称重,计算子宫指数。子宫指数=(子宫重量÷体重)×100%
在骨、子宫、肠、肝脏、肾脏组织学和组织形态学分析中,我们使用石蜡切片。首先将大鼠左股骨、子宫、肠、肝脏、肾脏组织固定在4%多聚甲醛(PFA)中,按照方案依次脱钙脱水,然后将其嵌入石蜡中,切片成4μm厚的切片。切片用苏木精和伊红(H&E)染色,光镜下观察组织结构。
将新鲜粪便样本(n=5只/组)收集在无菌管并储存在液氮中。采用粪便提纯DNA试剂盒,根据制造商的说明书提取粪便样品DNA,并通过凝胶电泳检测细菌基因组DNA。采用16S rRNA基因分析法对4组肠道细菌组成进行分析,将样本DNA扩增,用带有条形码的特定引物16S v3–v4 rDNA区域。引物序列为341F:CCTACGGGNGCWGCAG;806R:GGACTACHVGGTATCTAAT。利用QuantiFluor TM Qubit 3.0和ABI Steponeplus实时PCR系统回收并定量PCR扩增产物。将纯化的扩增产物等量混合,连接到测序适配器上构建测序库。最后,利用PE250平台在hiseq2500系统上对库进行排序,生成250bp的成对端读。使用qiime(v1.9.1)软件包(微生物生态学定量分析)分析序列。首先,读取被qiime质量过滤器过滤。接下来,我们为每个OTU(操作分类单元)选择代表性序列,并使用RDP(核糖体数据库项目)分类器(版本2.2)对每个代表性序列的分类信息进行注释。按大小降序排列的分类等级有域、门、类、目、科、属和种。鉴定了两组样品的属间差异。
2、实验结果。
(1)对血清CTX,BALP,TRACP5b,OPG骨代谢生化指标的检测。
酶联免疫吸附剂测定血清中的大鼠酒石酸酸性磷酸酶5b(TRACP-5b),骨源性碱性磷酸酶(BALP),I性胶原羧基末端肽(CTX)和骨保护素(OPG)水平,CTX、BALP和TRACP-5b含量显著升高与骨质疏松症有关,骨保护素是骨形成的标志物,结果见表2。模型组大鼠血清中四种成分的含量,与假手术对照组比较具有显著性差异,提示造骨质疏松模型成立;本发明降低了血清中CTX、BALP和TRACP-5b三种成分的含量,而提高了OPG的含量,提示本发明对骨质疏松有治疗作用。
组别 | CTX(nmol/L) | BALP(pg/ml) | TRACP5b(pg/ml) | OPG(pg/ml) |
假手术组 | 2.73±0.58 | 24.13±3.17 | 48.67±9.96 | 89.35±5.74 |
造模组 | 3.08±0.16# | 36.55±3.25## | 91.08±3.69## | 69.43±2.24## |
本发明组 | 2.74±0.07* | 26.26±3.68** | 60.12±5.20** | 91.15±4.14** |
己烯雌酚 | 2.43±0.38** | 24.14±3.57** | 61.69±4.73** | 84.63±5.37* |
(2)对去卵巢大鼠骨组织病理学的影响。
通过Micro-CT对大鼠左侧股骨进行扫描,病理诊断结果如图1所示。
假手术组:该组股骨骨小梁排列密集,互相连接呈网状结构,骨小梁密度大,间距减小。
模型组:骨小梁明显变细,数量明显减少,断裂增多,骨小梁密度明显减小,髓腔扩大,皮质骨变薄。与空白组比较骨小梁髓腔间距增大,造成了骨质疏松。
己烯雌酚组:与模型组比较骨小梁变得规则,数目增多,断裂减少,髓腔间隙变小,但骨小梁密度仍小于空白组。
本发明组:给本发明组合物后,骨小梁数量增多,密度明显增高,髓腔间隙变小,皮质骨变厚,提示本发明对骨质疏松有治疗作用。
(3)对肠道菌群的影响。
骨质疏松会导致肠道菌群紊乱,肠道菌群失调引起的炎症状态、自身免疫改变会导致骨质流失,骨形成减少。通过HE染色切片观察到,如图2所示,骨质疏松后小肠绒毛结构破坏,出现局灶性浅表固有层水肿,轻度炎症增加,上皮细胞损伤或丢失,杯状细胞形态不规则,而本发明能够明显调节这种紊乱,使其恢复至正常水平,从而增加骨密度,改善骨质疏松。与假手术相比,模型组在科水平,胃瘤球菌科、毛螺菌科、肠杆菌科、理研菌科的丰度异常升高,而普雷沃氏菌科、乳杆菌科的比例异常降低,而在本发明组,这些异常升高的菌科水平明显降低,乳杆菌科水平完全升高至正常水平,整体物种组成比例恢复至正常水平,如图3-1至图3-4所示。提示去势造模会导致大鼠肠道菌群紊乱,而本发明能够明显调节这种紊乱,使其恢复至正常水平。短链脂肪酸是肠道菌群的重要代谢产物,会促进肠道对矿物质的吸收,模型组粪便和血清中乙酸、丙酸、异丁酸、丁酸、异戊酸、戊酸含量均下降,如图4-1至图4-2所示,服用本发明组合物后,短链脂肪酸含量显著提高,特别是乙酸和丁酸含量显著增加。结合已有研究报道SCFA通过调节免疫相关的炎性因子或者直接作用于破骨细胞,可以发挥改善骨质疏松的作用。本发明可以通过调节肠道菌群促进矿物质的吸收从而调节骨代谢发挥抗骨质疏松作用。
二、安全性评价。
服用本发明三个月的大鼠精神状态良好,皮毛光亮,自主活动正常,子宫指数正常,维持子宫正常形态,肝功、肾功正常,体重平稳下降,纠正肠道菌群失衡,增加益生菌,增加肠壁完整性,维持肠道稳态,对白细胞、红细胞、血小板均无任何影响,安全有效。而服用雌激素己烯雌酚三个月后的大鼠体态消瘦,无精打采,皮毛暗淡,行动迟缓,子宫肿大,子宫内膜增生,转氨酶、尿素、肌酐异常增高,肝脏肿大,肾脏发黑,肝小叶萎缩,肝细胞排列不规则,肾小球空泡,肝肾损伤严重,体重急剧下降,肠道菌群失调,红细胞和血红蛋白数量偏低,引起轻度贫血。因此,本发明通过改善肠道菌群显著增加骨密度,同时辅助降血脂,无不良反应,适宜长期服用。
三、人体试食评价。
经50例骨质疏松患者(年龄50-70)服用本产品三个月,回馈均有效改善和缓解骨质疏松造成的疼痛症状,筋骨舒展,排便规律,体重稳步下降。
Claims (9)
1.一种通过调节肠道菌群增加骨密度的多功能食品组合物,其特征在于,由如下重量份数的组分组成:黄瓜籽粉20~25份、葛根8~20份、覆盆子8~15份、黑芝麻2~4份、牡蛎2~4份、茯苓2~4份、菊粉1~3份、白芸豆粉1~2份。
2.如权利要求1所述的多功能食品组合物,其特征在于,由如下重量份数的组分组成:黄瓜籽20份、葛根20份、覆盆子10份、黑芝麻3份、牡蛎4份、茯苓3份、菊粉3份、白芸豆粉1份。
3.如权利要求1所述的多功能食品组合物,其特征在于,由如下重量份数的组分组成:黄瓜籽25份、葛根15份、覆盆子10份、黑芝麻2份、牡蛎2份、茯苓3份、菊粉2份、白芸豆粉2份。
4.如权利要求1所述的多功能食品组合物,其特征在于,由如下重量份数的组分组成黄瓜籽粉24份、葛根8份、覆盆子8份、黑芝麻4份、牡蛎2份、茯苓2份、菊粉2份、白芸豆粉1份。
5.如权利要求1所述的多功能食品组合物的制备方法,其特征在于,该制备方法包括以下步骤:
步骤1、将所述各组分原料除杂、净化、晾干后备用;
步骤2、将葛根、覆盆子、黑芝麻、茯苓在80℃的烘箱中烘干5h,再粉碎,过120目筛,得到细粉混合物A;
步骤3、牡蛎直接粉碎,合并黄瓜籽粉、菊粉和白芸豆粉过100目筛,得到细粉混合物B;
步骤4、将混合物A与混合物B均匀混合后制得所需剂型。
6.如权利要求1所述的多功能食品组合物在制备增加骨密度、改善肠道菌群的的药物、食品和保健品中的用途。
7.如权利要求6所述的用途,其特征在于,所述的多功能食品组合物加入辅料制备成不同制剂,所加入的辅料为药学上可接受的辅料。
8.如权利要求7所述的用途,其特征在于,所述药物的剂型为颗粒剂、片剂、胶囊剂、袋泡剂、泡腾剂、散剂、口服液、丸剂。
9.如权利要求8所述的用途,其特征在于,所述药物的剂型为颗粒剂、片剂、胶囊剂和袋泡剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110399300.1A CN115251339A (zh) | 2021-04-14 | 2021-04-14 | 一种通过调节肠道菌群增加骨密度的功能食品组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110399300.1A CN115251339A (zh) | 2021-04-14 | 2021-04-14 | 一种通过调节肠道菌群增加骨密度的功能食品组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115251339A true CN115251339A (zh) | 2022-11-01 |
Family
ID=83745829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110399300.1A Pending CN115251339A (zh) | 2021-04-14 | 2021-04-14 | 一种通过调节肠道菌群增加骨密度的功能食品组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115251339A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102524800A (zh) * | 2012-02-03 | 2012-07-04 | 张博仑 | 一种复合黄瓜籽粉及其制备方法 |
CN105558586A (zh) * | 2014-10-09 | 2016-05-11 | 刘海燕 | 一种黄瓜籽补钙含片工艺及其制备方法 |
CN107823251A (zh) * | 2017-11-21 | 2018-03-23 | 李新梅 | 一种营养骨质防止骨质疏松的中药组分 |
CN110973335A (zh) * | 2020-01-15 | 2020-04-10 | 吉林人参研究院(吉林省长白山天然药物研究院) | 一种增加骨密度的压片糖果及其制备方法 |
CN111657467A (zh) * | 2019-10-12 | 2020-09-15 | 刘树江 | 补钙制剂及其制备方法 |
JP2020189799A (ja) * | 2019-05-21 | 2020-11-26 | フジ日本精糖株式会社 | イヌリンを含む筋肉量減少抑制又は骨密度減少抑制剤 |
-
2021
- 2021-04-14 CN CN202110399300.1A patent/CN115251339A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102524800A (zh) * | 2012-02-03 | 2012-07-04 | 张博仑 | 一种复合黄瓜籽粉及其制备方法 |
CN105558586A (zh) * | 2014-10-09 | 2016-05-11 | 刘海燕 | 一种黄瓜籽补钙含片工艺及其制备方法 |
CN107823251A (zh) * | 2017-11-21 | 2018-03-23 | 李新梅 | 一种营养骨质防止骨质疏松的中药组分 |
JP2020189799A (ja) * | 2019-05-21 | 2020-11-26 | フジ日本精糖株式会社 | イヌリンを含む筋肉量減少抑制又は骨密度減少抑制剤 |
CN111657467A (zh) * | 2019-10-12 | 2020-09-15 | 刘树江 | 补钙制剂及其制备方法 |
CN110973335A (zh) * | 2020-01-15 | 2020-04-10 | 吉林人参研究院(吉林省长白山天然药物研究院) | 一种增加骨密度的压片糖果及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102885304B (zh) | 一种增加骨密度的保健食品组合物及其制备方法 | |
CN103599490B (zh) | 一种治疗牙周炎的中药丸剂制备方法 | |
CN103798595A (zh) | 一种增加骨密度的保健食品及其制备方法 | |
CN109602794A (zh) | 一种治疗骨关节炎的中药组合物及制备方法和用途 | |
CN103721242A (zh) | 一种药物组合物在预防或治疗骨质疏松中的新用途 | |
US10758580B2 (en) | Composition of sea buckthorn pulp oil and panax notoginseng saponins for treating osteoporotic fracture and/or osteoarthritis and uses thereof | |
CN113713067B (zh) | 用于防治肌少骨质疏松症的中药组合物及其制备方法 | |
CN104042837B (zh) | 一种用于骨及骨关节退行性病变的药物组合物 | |
US6344217B1 (en) | Putamen OVI | |
CN101292739A (zh) | 一种具有增加骨密度功能的保健食品 | |
CN108938989B (zh) | 一种治疗骨质疏松症的覆茴精健骨散 | |
CN105770850A (zh) | 一种辅助治疗骨关节疾病的保健品及其制备方法 | |
CN115251339A (zh) | 一种通过调节肠道菌群增加骨密度的功能食品组合物及其制备方法 | |
CN103877140A (zh) | 雪莲培养物在制备促进骨骼健康产品中的应用 | |
CN112971121A (zh) | 一种增加骨密度、调节肠道菌群的功能食品组合物及其制备方法 | |
CN109601880B (zh) | 一种增加骨密度的保健食品 | |
CN1895504A (zh) | 一种治疗骨质疏松症的中药及制备方法 | |
CN114558088B (zh) | 一种治疗原发性骨质疏松症的蒙药复方及其应用 | |
CN104523685A (zh) | 去铁斯若在制备治疗绝经后骨质疏松疾病药物中的用途 | |
CN106075376A (zh) | 一种治疗骨折的口服制剂 | |
CN109331187A (zh) | 间充质干细胞制剂致敏性的评价方法和应用 | |
Fan et al. | Protective Effect of Panax ginseng on osteoporosis in Ovariectomized Female Guinea-pigs | |
CN103251935A (zh) | 一种含有鹿茸的药用组合物及应用 | |
CN112891366B (zh) | 一种治疗绝经后骨质疏松症的中药活性成分组方及其应用 | |
CN107982409B (zh) | 一种治疗脊髓空洞症的中药组合物、丸剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |